COMPARISON OF PAIN SCORE IN OSTEOARTHRITIS PATIENTS TREATED WITH A COMBINATION OF DIACEREIN AND MELOXICAM AND MELOXICAM ALONE

Authors

  • Ni Made Oka Dwicandra Departement of Clinical Pharmacy, Institut Ilmu Kesehatan Medika Persada Bali
  • Antonious Adji Prayitno Setiadi University of Surabaya

DOI:

https://doi.org/10.22159/ijpps.2017v9i6.17671

Keywords:

Osteoarthritis, Diacerein, Meloxicam, Pain intensity

Abstract

Objective: Osteoarthritis (OA) is a progressive chronic disease with the loss of articular cartilage. In managing OA, inadequate pain relief (IPR) often occurs, particularly with a single non steroidal anti-inflammatory drugs (NSAIDs) therapy. In this research, pain outcome of OA patients treated with a combination of diacerein and meloxicam vs meloxicam alone was evaluated.

Methods: This research was conducted at rumah sakit umum daerah (RSUD) Dr. Mohammad Soewandhie Surabaya by using randomized controlled trial (RCT) design. Pain outcome was evaluated by pain intensity and area under the curve (AUC) of pain score in week 0-4th.

Results: There were a significantly different (p<0.05) in pain intensity seen in 3rd and 4th weeks after treated with a combination of diacerein and meloxicam, and with meloxicam only. However, there were no different in AUC pain score between combination and single therapy.

Conclusion: Combination therapy of diacerein and meloxicam was more effective than meloxicam alone. A significant effect of a combination therapy of diacerein and meloxicam occurred at 3rd weeks. The prolong study in order to get the differences in AUC pain score are needed.

Downloads

Download data is not yet available.

References

Alldredge BK, Affairs A, Francisco S, Corelli RL, Ernst ME, City I, et al. Koda-Kimble and Young’s Applied Therapeutic: The Clinical Use of Drug. 10th ed. Philadelphia: Lippincot Williams and Wilkins; 2013.

The Indonesian Rheumatism Association. Diagnosis dan Penatalaksanaan Osteoartritis. Jakarta: The Indonesian Rheumatism Association; 2014.

Jena M, Mishra S, Pradhan S, Jena S, Mishra SS. Chronic pain, its management and psychological issues: a review. Asian J Pharm Clin Res 2015;8:42–7.

Åastowiecka E, Bugajska J, Najmiec A, Rell-Bakalarska M, Bownik I, Jedryka-Góral A. Occupational work and quality of life in osteoarthritis patients. Rheumatol Int 2006;27:131–9.

Tak S, Laffrey S. Life satisfaction and its correlates in older women with osteoarthritis. Orthopaedic Nursing 2003;22:182–9.

Conaghan P, Rannou F, Arden N, Everett SV, Balshaw R, Peloso PM, et al. Inadequate pain relief (IPR) in knee osteoarthritis: what does it look like? a European survey of osteoarthritis real world therapies (SORT). Osteoarthritis and Cartilage J 2012;20:S178.

Jameson K, Balshaw R, Phillips C, Martin GR, Everett SV, Watson DJ, et al. PMS59 inadequate pain relief in knee osteoarthritis and patient reported outcomes: a survey of osteoarthritis real world therapies (SORT) in the United Kingdom. Value Health 2011;14:A313.

Conaghan PG, Peloso PM, Everett SV, Rajagopalan S, Black CM, Mavros P, et al. Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies. Rheumatology (Oxford) 2015;54:270–7.

Mercadante S, Casuccio A, Agnello A, Pumo S, Kargar J, Garofalo S. Analgesic effects of nonsteroidal anti-inflammatory drugs in cancer pain due to somatic or visceral mechanisms. J Pain Symptom Manage 1999;17:351–6.

Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011;27:2361–72.

Ohtori S, Inoue G, Orita S, Takaso M, Eguchi Y, Ochiai N. Efficacy of combination of meloxicam and pregabalin for pain in knee osteoarthritis. Yonsei Med J 2013;54:1253–8.

Colville-Nash P, Willoughby D. COX-1, COX-2 and articular joint disease: a role for chondroprotective agents. Biorheology 2002;39:171–9.

Fidelix T, Macedo C, Maxwell L, Fernandes Moça Trevisani V. Diacerein for osteoarthritis. Cochrane Database of Systematic Reviews; 2014.

Medhi B. Diacerein: a new disease modulating agent in osteoarthritis. Indian J Physical Med Rehabilitation 2007;18:48–52.

Mahajan A, Singh K, Tandon VR, Kumar S, Kumar H. Diacerein: a new symptomatic slow acting drug for Osteoarthritis. JK Sci 2006;8:173–5.

Lee AS, Ellman MB, Yan D, Kroin JS, Cole BJ, van Wijnen AJ, et al. A current review of molecular mechanisms regarding osteoarthritis and pain. Gene 2013;527:440–7.

Kongtharvonskul J, Anothaisintawee T, McEvoy M, Attia J, Woratanarat P, Thakkinstian A. Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis. Eur J Med Res 2015;20:1–11.

Rintelen B, Neumann K, Leeb B. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med 2006;166:1889–906.

Bartels EM, Bliddal H, Schøndorff PK, Altman RD, Zhang W, Christensen R. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage 2010;18:289–96.

Pelletier J, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, et al. Efficacy and safety of diacerein in osteoarthritis of the knee. Arthritis Rheum 2000;43:2339–48.

Pavelka K, Trc T, Karpas K, Vítek P, Sedlácková M, Vlasáková V, et al. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period. Arthritis Rheum 2007;56:4055–64.

Mirunalini R, Chandrasekaran M, Manimekalai K. Efficacy of chondroitin sulfate with glucosamine versus diacerein in grade ii and iii osteoarthritis knee: a randomized comparative study. Asian J Pharm Clin Res 2015;8:42–4.

Yocum D, Fleischmann R, Dalgin P, Caldwell J, Hall D, Roszko P. Safety and efficacy of meloxicam in the treatment of osteoarthritis a 12-week, double-blind, multiple-dose, placebo-controlled trial. Arch Intern Med 2000;160:2947–54.

Lund B, Distel M, Bluhmki E. A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. Scand J Rheumatol 1998;27:32–7.

Goei HS, Lund B, Distel M, Bluhmki E. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 1997;5:283–8.

Zeidler H, Kaltwasser J, Leonard J, Kohlmann T, Sigmund R, Degner F, et al. Prescription and tolerability of meloxicam in day-to-day practice: postmarketing observational cohort study of 13,307 patients in Germany. J Clin Rheumatol 2002;8:305–15.

Tacca M Del, Colucci R, Fornai M, Blandizzi C. Efficacy and tolerability of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug. Clin Drug Inves 2002;11:1–22.

Dipiro J, Talbert R, Yee G, Matzke G, Wells B, Posey L. Pharmacotherapy: pathophysiologic approach. 7th ed. USA: The McGraw-Hill Companies, Inc; 2008.

Gupta N, Datta S. Efficacy and safety of diacerein and diclofenac in knee osteoarthritis in Indian patients-a prospective randomized open label study. J Biomed Sci 2012;1:1–14.

Shafshak TS, Shaheen EM, Hussein N, Hafez AA. The efficacy of diacerein with and without diclofenac sodium on knee pain severity and walking time in patients with knee osteoarthritis. Indian J Sci Res 2014;3:2012–5.

Rena K, Torres R. Role of interleukin-1β during pain and inflammation. Brain Res Rev 2011;60:57–64.

Lee CJ, Lee LH, Wu CL, Lee BR, Chen ML. Clinical trials of drug and biopharmaceuticals. USA: Taylor and Francis Group; 2006.

Pham B, Cranney A, Boers M, Verhoeven A, Wells G, Tugwell P. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials. J Rheumatol 1999;26:712–6.

Schiff M. A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapies. Clin Ther 2003;25:993–1001.

Singh K, Sharma R, Rai J. Diacerein as adjuvant to diclofenac sodium in osteoarthritis knee. Int J Rheum Dis 2012;15:69–77.

Tonelli SM, Rakel BA, Cooper NA, Angstom WL, Sluka KA. Women with knee osteoarthritis have more pain and poorer function than men, but similar physical activity prior to total knee replacement. Biol Sex Differ 2011;2:1–12.

Oyeyemi AL. Body mass index, pain and function in individuals with knee osteoarthritis. Nigerian Med J 2013;54:230–5.

Published

01-06-2017

How to Cite

Dwicandra, N. M. O., and A. A. P. Setiadi. “COMPARISON OF PAIN SCORE IN OSTEOARTHRITIS PATIENTS TREATED WITH A COMBINATION OF DIACEREIN AND MELOXICAM AND MELOXICAM ALONE”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 9, no. 6, June 2017, pp. 69-73, doi:10.22159/ijpps.2017v9i6.17671.

Issue

Section

Original Article(s)